REGN
REGENERON PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 21 ▲ Regeneron announced positive Phase 3 NIMBLE trial results for cemdis…
- May 1 to May 15 ▼ 2 sells: Ro Khanna, Gilbert Cisneros sold $1,001 - $15,000, last disclosed Jun 11
- Aug 14 ▲ Short interest falls 29.2% to 2.40M
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 14 ▼ 1 insider sell $277.5K at $764.47
- Oct 15 ▲ UBS upgrades
- Oct 30 to Nov 4 ▼ 4 days of insider sells: $46.4M by 8 insiders, avg $958.00
- Oct 30 ▲ Regeneron reported Q3 2026 revenue of $5.116B (up 36% YoY) and GAAP…
- Nov 2 The United States of America et al v. Regeneron…
- Nov 3 Trial readout: Results Pending: Dupilumab (Phase 3), completed 25d ago
- Nov 6 Trial readout: Results Pending: Ravulizumab (Phase 3), completed 39d ago
- Nov 12 FDA: POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR…
Signal stack
Where each data set points today.
- InsidersBEARISH
9 insiders sold $46.6M.
- InstitutionsBULLISH
Q3 2026: 66 added (3 new), 29 trimmed or exited.
- AnalystsBULLISH
26 of 36 rate it Buy or better. Median target $997.00 (+5%).
- Short sellersSTEADY
Short interest +3.9% to 2.22M shares. 2.7 days to cover, ≈2.1% of shares.
- TrendUPTREND
16% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 8.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FIRST TRUST ADVISORS LP | ADD | $626.9M |
| DEUTSCHE BANK AG\ | ADD | $521.2M |
| NORDEA INVESTMENT MANAGEMENT AB | ADD | $450.6M |
| BARCLAYS PLC | ADD | $264.2M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $206.4M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $202.1M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $181.7M |
| MARSHALL WACE, LLP | DOUBLED | $162.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
36 analystsPrice is inside the target range. Median implies +5%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Leerink Partners MAINTAIN | Market Perform |
| Nov 2, 2026 | Bernstein MAINTAIN | Market Perform |
| Nov 2, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 2, 2026 | Truist Securities MAINTAIN | Buy |
| Nov 2, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Nov 2, 2026 | Guggenheim MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Pitofsky Jason SVP Controller Nov 4, 2026 | EXERCISE | $1.1M |
Pitofsky Jason SVP Controller Nov 4, 2026 | EXERCISE | $952.6K |
Pitofsky Jason SVP Controller Nov 4, 2026 | EXERCISE | $445.3K |
Pitofsky Jason SVP Controller Nov 4, 2026 | SELL | $1.1M |
Pitofsky Jason SVP Controller Nov 4, 2026 | SELL | $499.1K |
Pitofsky Jason SVP Controller Nov 4, 2026 | SELL | $102.0K |
Pitofsky Jason SVP Controller Nov 4, 2026 | SELL | $33.1K |
Pitofsky Jason SVP Controller Nov 4, 2026 | SELL | $170.2K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
38 filings · 15 press releases · 11 bullish · 2 bearish · 1 mixed · 24 neutral- NEUTRAL 144Nov 16, 2026
George L. Sing, a director of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 1,000 shares of common stock with an approximate market value of $960,264. The shares were acquired in a private acquisition from the issuer in 1991.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 16, 2026
Marion McCourt, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 566 shares of common stock, valued at approximately $545,239. The shares were acquired via RSA vesting on December 12, 2023.
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASENov 12, 2026
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a…
Phase 3 trial initiation in H1 2027 is the next catalyst. Monitor for regulatory feedback and any competitive developments in the POTS space. The Phase 2 data are early but address a high unmet need.
- NEUTRAL CLUSTERNov 5, 2026
Seven Regeneron insiders sold a total of $9.56M in open-market sales over the week following a…
The sales are small relative to market cap and occur after a strong earnings beat, suggesting routine portfolio diversification rather than negative signaling. Monitor next quarter's insider…
All REGN filing & press-release reports (53)
- 144 reportNov 16, 2026
- 144 reportNov 16, 2026
- PRESS-RELEASE reportNov 12, 2026
- CLUSTER reportNov 5, 2026
- CLUSTER reportNov 5, 2026
- 144 reportNov 4, 2026
- CLUSTER reportNov 3, 2026
- 144 reportNov 4, 2026
- COURT-RULING reportNov 2, 2026
- 144 reportNov 3, 2026
- CLUSTER reportNov 3, 2026
- 144 reportNov 2, 2026
- 144 reportNov 2, 2026
- 144 reportNov 2, 2026
- 144 reportOct 30, 2026
- 144 reportOct 30, 2026
- 144 reportOct 30, 2026
- 8-K reportOct 30, 2026
- PRESS-RELEASE reportOct 30, 2026
- PRESS-RELEASE reportOct 26, 2026
- PRESS-RELEASE reportOct 25, 2026
- INST-CLUSTER reportOct 23, 2026
- UBS upgrades REGN to Buy, PT $978 (+25.6%)Oct 15, 2026
- 144 reportOct 14, 2026
- 8-K reportOct 6, 2026
- PRESS-RELEASE reportOct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- Argus Research upgrades REGN to Buy, PT $850 (+12.1%)Oct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- GOVT-CONTRACT reportSep 25, 2026
- PRESS-RELEASE reportSep 24, 2026
- CLUSTER reportSep 3, 2026
- COURT-RULING reportAug 24, 2026
- CLUSTER reportAug 12, 2026
- COURT-RULING reportAug 11, 2026
- PRESS-RELEASE reportJul 30, 2026
- 8-K reportJul 30, 2026
- COURT-RULING reportJul 7, 2026
- Benchmark upgrades REGN to Buy, PT $185 (-71.5%)Jul 7, 2026
- 8-K reportJul 6, 2026
- PRESS-RELEASE reportJun 22, 2026
- PRESS-RELEASE reportMay 21, 2026
- Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform, PTs slashed to $700/$641; stock near PT levelsMay 18, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- DEFA14A reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- 8-K reportApr 8, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- COURT-RULING reportMar 30, 2026
- PRESS-RELEASE reportMar 25, 2026